ClinicalTrials.gg
CompletedNCT01167010UNIKUpdated May 1, 2025Results posted

A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma

A Phase 3 interventional study of Formoterol/Budesonide and Foraseq in Asthma, sponsored by Eurofarma Laboratorios S.A.. Completed at 5 sites in Brazil. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
24th of 85
552 · median 100
Started
2011
with 2 others
Phase 3
48 of 86
2 open now
Registered
52nd of 86
by date
Lead sponsor
3 of 86
Eurofarma Laboratorios S.A.

Among the 86 studies testing formoterol in Asthma, this one is the 24th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2011, is one of 48 in phase 3, and was the 52nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the three study formulations regarding the clinical control of the symptoms and the patients' compliance to the treatment.

Read the detailed description

The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the three study formulations regarding the clinical control of the symptoms and the patients' compliance to the treatment.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the ICF;
  • ≥ 12 years old;
  • Have a diagnosis of mild to moderate persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test \<3,0;
  • Current use of inhaled (equivalent to 1000 µg of beclomethasone dipropionate) whether associated or not with long-term β2 adrenergics and relief medication (salbutamol or equivalent);
  • Initial of at least 50% of the normal value expected;
  • Serum cortisol evaluation within the normal limits

Exclusion criteria

Exclusion Criteria:

  • Use of oral or parenteral within the last 3 months before the study;
  • Hospitalization needed due to asthma within the last 3 months before the study;
  • Active smokers, defined as the consumption of cigarettes, pipes, cigars, or any other form of smoking in any amount within the last 3 months;
  • Presence of serious co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatologic, neurological, or psychiatric disease, or chronic respiratory disease other than asthma;
  • Recent participation (\<6 months) or expected participation in other clinical trials involving drug products of any nature or in studies consisting of any form of intervention for the treatment of asthma;
  • Intolerance or allergy to any component of the drugs evaluated in the study;
  • Pregnant or lactating women;
  • Chronic use of routine β-blockers orally or intravenously, including ophthalmic solutions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
552 participants (actual)

Study arms

  • Experimental
    Formoterol/Budesonide

    formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.

    Drug: Formoterol/Budesonide

  • Active comparator
    Foraseq

    Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

    Drug: Foraseq

  • Active comparator
    Alenia

    Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

    Drug: Alenia

Interventions

  • DrugFormoterol/Budesonide

    Drug pages: Formoterol · Budesonide

    formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

  • foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

    Also known as: Formoterol/Budesonide

  • DrugAlenia

    Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

    Also known as: Formoterol/Budesonide

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)

    The primary efficacy analysis was performed by evaluating non-inferiority of Eurofarma's device compared to Alenia® in relation to FEV1 (in liters) in FV in the PP population

    Time frame: 12 weeks

Secondary outcomes

  1. FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups

    The mean FEV1 (L) in VF were compared between the three groups using the nonparametric Kruskal-Walllis test and the ITT population. A nonparametric test was used since the variable did not show normal distribution in the Foraseq® group.

    Time frame: 12 weeks

07

Results

Posted May 1, 2025

Participant flow

Participant flow — Overall Study
MilestoneFormoterol/BudesonideForaseqAlenia
Started184184184
Completed154145151
Not completed303933

Outcome measures

PrimaryForced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)

The primary efficacy analysis was performed by evaluating non-inferiority of Eurofarma's device compared to Alenia® in relation to FEV1 (in liters) in FV in the PP population

Time frame:
12 weeks
Reported as:
Mean · Liter
Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)
LiterFormoterol/BudesonideAlenia
Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)2.53 ± 0.792.51 ± 0.77
SecondaryFEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups

The mean FEV1 (L) in VF were compared between the three groups using the nonparametric Kruskal-Walllis test and the ITT population. A nonparametric test was used since the variable did not show normal distribution in the Foraseq® group.

Time frame:
12 weeks
Reported as:
Mean · Liter
FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups
LiterAleniaFormoterol/BudesonideForaseq
FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups2.49 ± 0.772.52 ± 0.802.46 ± 0.88

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Formoterol/Budesonide—1/154 (0.6%)1/154 (0.6%)
Foraseq—0/145 (0%)0/145 (0%)
Alenia—0/151 (0%)0/151 (0%)
Most frequent serious events
Most frequent serious events
EventFormoterol/BudesonideForaseqAlenia
ThrombocytopeniaBlood and lymphatic system disorders1/1540/1450/151
LeukopeniaImmune system disorders1/1540/1450/151
Most frequent other events
Most frequent other events
EventFormoterol/BudesonideForaseqAlenia
Left and posterior knee trauma infectionInjury, poisoning and procedural complications1/1540/1450/151

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Formoterol/BudesonideForaseqAleniaTotal
<=18 years28252174
Between 18 and 65 years119112121352
>=65 years78924
Age, Continuous
Age, Continuous(years)Formoterol/BudesonideForaseqAleniaTotal
Mean38 ± 1739 ± 1739 ± 1639 ± 17
Sex: Female, Male
Sex: Female, Male(Participants)Formoterol/BudesonideForaseqAleniaTotal
Female9999110308
Male554641142
Region of Enrollment
Region of Enrollment(participants)Formoterol/BudesonideForaseqAleniaTotal
Brazil154145151450
08

Study locations

5 sites
  • Centro de Referencia em Enfermidades Respiratoria e Alergica
    Salvador, BA, Brazil
  • Hospital de Clinicas UFPR
    Curitiba, PR, Brazil
  • Clinica de Alergia Martti Antila
    Sorocaba, SP, Brazil
  • IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada
    São Paulo, SP, Brazil
  • Stelmach Pesquisa Clinica
    São Paulo, SP, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2025, 13 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2010
First posted
Jul 21, 2010
Start
Apr 2011
Primary completionActual
Aug 2011
CompletionActual
Feb 2012
Results first posted
May 1, 2025
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01167010
Responsible party
Sponsor
First posted
Jul 21, 2010
Start date
Apr 2011
Primary completion
Aug 2011
Completion
Feb 2012
Results posted
May 1, 2025
Last update
May 1, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Formoterol · Budesonide

Start the discussion